| Literature DB >> 25141915 |
Yonghua Chen, Xing Wang, Nengwen Ke, Gang Mai, Xubao Liu1.
Abstract
BACKGROUND: Tumors of the pancreatic head often involve the superior mesenteric and portal veins. The purpose of this study was to assess perioperative outcomes after pancreaticoduodenectomy (PD) with concomitant vascular resection using the inferior mesenteric vein (IMV) as a guide for transection of the pancreatic body (Whipple at IMV, WATIMV).Entities:
Mesh:
Year: 2014 PMID: 25141915 PMCID: PMC4237777 DOI: 10.1186/s40001-014-0042-z
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Figure 1Magnetic resonance imaging (MRI) of a patient with segmental vein occlusion. A) A mass with complete occlusion of the superior mesenteric vein (SMV) (arrow); B) A multiple planar volume reconstruction image showed complete occlusion of the SMV with a venous collateral (arrow); the inferior mesenteric vein (IMV) inserted into the splenic vein (SV). PV, portal vein.
Figure 2Schematic diagram. A) Pancreatic tumors involving the anterior of the mesenterico-portal vein (MPV) axis (circles); line A indicates the usual plane of transection of the neck of the pancreas in a standard Whipple procedure; line B indicates the plane of transection in an interior mesenteric vein (IMV) procedure; line C indicates the plane of transaction as in the ‘central pancreatectomy’ approach. B) The pancreas is transected just to the right of the plane through which the IMV enters the inferior border of the pancreas. (PV, portal vein; HA, hepatic artery; SA, splenic artery; SMV, superior mesenteric vein; SMA, superior mesenteric artery; SV, splenic vein).
Figure 3Intraoperative photographs. A) creating the tunnel between the anterior surface of the splenic vein (SV) and the posterior surface of the pancreas; the body of the pancreas was encircled with a vessel loop; B) The superior mesenteric vein (SMV) has been anastomosed to the portal vein (PV) without a graft. (Reprinted from: Chen YH et al., J Am Coll Surg 2013, 217(4):E21-E28., with permission).
Clinical characteristics, operative data, postoperative outcomes, and histopathologic features
| Age (yr) (mean (SD)) | 57.8 ± 10.9 | 57.2 ± 10.9 | 58.1 ± 11.1 | 56.3 ± 10.8 | 0.398 | 0.63 | 0.87 |
| Sex (Male/Female) | 38/24 | 19/9 | 19/15 | 51/24 | 0.41 | 0.48 | 0.99 |
| ASA score, n | | | | | 0.75 | 0.89 | 0.96 |
| 1 | 28 | 13 | 15 | 35 | | | |
| 2 | 24 | 10 | 14 | 25 | | | |
| 3 | 10 | 5 | 5 | 15 | | | |
| Operative data | | | | | | | |
| Length of vein resection, mm (95% CI) | 24.19 (22.93 to 25.46) | 24.64 (22.67 to 26.61) | 23.82(22.1 to 25.54) | 20.91 (19.39 to 22.42) | 0.002 | 0.59 | 0.005 |
| Blood loss, mL (95% CI) | 679.8 (557.1 to 802.5) | 533.9 (426.7 to 641.2) | 800(597.8 to 1002.2) | 509.3 (442.7 to 575.9) | 0.018 | 0.013 | 0.79 |
| Blood loss 500 mL, n | 36 | 13 | 23 | 27 | 0.01 | 0.012 | 0.99 |
| Blood transfusion, n | 31 | 10 | 20 | 21 | 0.008 | 0.07 | 0.45 |
| Histopathology | | | | | | | |
| Tumor differentiation, n | | | | | 0.41 | 0.97 | 0.66 |
| Well | 0 | 0 | 0 | 2 | | | |
| Moderate | 22 | 10 | 12 | 28 | | | |
| Poor | 40 | 18 | 22 | 45 | | | |
| Overall stage a, n | | | | | 0.14 | 0.58 | 0.52 |
| 1B | 0 | 0 | 0 | 3 | | | |
| 2A | 34 | 16 | 17 | 47 | | | |
| 2B | 29 | 12 | 17 | 24 | | | |
| 3 | 0 | 0 | 0 | 0 | | | |
| 4 | 0 | 0 | 0 | 1 | | | |
| Neural invasion, n | 39 | 18 | 21 | 24 | 0.001 | 0.84 | 0.003 |
| Vascular invasion, n | 46 | 21 | 25 | 27 | 0.001 | 0.895 | 0.001 |
| Depth of venous wall invasion, No | | | | | 0.001 | 0.56 | 0.001 |
| Adventitia | 9 | 3 | 6 | 11 | | | |
| Tunica media | 24 | 10 | 14 | 10 | | | |
| Intima | 13 | 8 | 5 | 6 | | | |
| Lymph node metastasis, n | 29 | 12 | 17 | 25 | 0.11 | 0.58 | 0.37 |
| R1 Margin, n | 9 | 1 | 8 | 5 | 0.13 | 0.06 | 0.9 |
| Site of positive margin (no. (%)) | | | | | | | |
| Pancreas | 3 | 0 | 3 | 1 | | | |
| Retroperitoneum | 6 | 1 | 5 | 4 | | | |
| Postoperative data | | | | | | | |
| Medical complications, n | 30 | 13 | 17 | 35 | 0.84 | 0.78 | 0.98 |
| Grade of complications | | | | | 0.09 | 0.83 | 0.057 |
| 0 | 32 | 15 | 17 | 40 | | | |
| 1 | 9 | 4 | 5 | 13 | | | |
| 2 | 13 | 5 | 8 | 16 | | | |
| 3 | 7 | 4 | 3 | 1 | | | |
| 4 | 0 | 0 | 0 | 4 | | | |
| 5 Mortality, n | 1 | 0 | 1 | 1 | | | |
| Postoperative hospital stay (days) (mean (SD)) | 17 ± 9.7 | 15 ± 7.1 | 18.6 ± 11.3 | 14.2 ± 5.8 | 0.55 | 0.095 | 0.67 |
aAmerican Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition.
PbPatients who underwent standard PD with vein resection procedure (s-PD + VR, n = 75) versus modified procedure (m-PD + VR, n = 62).
PcFurther stratification of the entire cohort of m-PD + VR group, ‘Whipple at IMV’ procedure (WATIMV n = 28) versus transection procedure as in the ‘central pancreatectomy’ (c-PD + VR, n = 34); P dPatients who underwent standard PD with vein resection procedure (s-PD + VR, n = 75) versus ‘Whipple at IMV’ procedure (WATIMV, n = 28). ASA, American Society of Anesthesiologists; WATIMV, Whipple at inferior mesenteric vein.
Univariate and multivariate logistic regression analyses of predictors of postoperative complications
| Age, y | 0.99 (0.96, 1.03) | 0.72 | | |
| Sex | | | | |
| Male | 0.61 (0.30, 1.23) | 0.17 | | |
| Female | 1.0 | | | |
| Resection | | 0.22 | | |
| S-PD | 1.0 | | | |
| c-PD | 1.29 (0.57, 2.90) | 0.54 | | |
| IMV | 0.99 (0.42, 2.37) | 0.98 | | |
| ASA score | | 0.001 | | 0.003 |
| 1 | 1.0 | | | |
| 2 | 3.99 (1.81, 8.80) | 0.001 | 3.88 (1.66, 9.10) | 0.002 |
| 3 | 4.12 (1.55, 10.95) | 0.005 | 3.68 (1.26. 10.74) | 0.017 |
| Blood loss, mL | 1.001 (1.0, 1.003) | 0.006 | | NS |
| Blood loss >500 mL | | | | NS |
| Yes | 2.497 (1.25, 4.98) | 0.009 | | |
| No | 1.0 | | | |
| Blood transfusion | | | 3.179 (1.43, 7.06) | 0.004 |
| Yes | 3.88 (1.86, 8.11) | <0.001 | | |
| No | 1.0 | | | |
| Neural invasion | | | | NS |
| Present | 1.54 (0.78, 3.03) | 0.21 | | |
| Absent | 1.0 | | | |
| Vascular invasion | | | 2.87 (1.32, 6.21) | 0.008 |
| Present | 2.53 (127, 5.05) | 0.008 | | |
| Absent | 1.0 | | | |
| Lymph node metastasis | | | | NS |
| Present | 1.85 (0.92, 3.698) | 0.08 | | |
| Absent | 1.0 | | | |
| Tumor differentiation | 2.49 (1.25, 4.96) | 0.009 | | NS |
| Overall stage b | 1.69 (0.91, 3.13) | 0.096 | NS | |
Values in parentheses are 95% confidence intervals.
aLogistic regression.
bAmerican Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition. ASA, American Society of Anesthesiologists.
Univariate and multivariate logistic regression analyses of predictors of positive resection margin
| Age, y | 0.98 (0.94, 1.03) | 0.489 | | |
| Sex | | | | |
| Male | 0.69 (0.23, 2.12) | 0.519 | | |
| Female | 1.0 | | | |
| Resection | | 0.22 | | NS |
| S-PD | 1.0 | | | |
| c-PD | 4.31 (1.29, 14.37) | 0.017 | | |
| IMV | 0.52 (0.06, 4.65) | 0.557 | | |
| ASA score | | 0.721 | | |
| 1 | 1.0 | | | |
| 2 | 1.62 (0.46, 5.56) | 0.450 | | |
| 3 | 1.58 (0.35, 7.18) | 0.553 | | |
| Length of vein resection, | 1.01 (0.92, 1.11) | 0.764 | | |
| Blood loss, mL | 1.003 (1.001, 1.004) | <0.001 | 1.003 (1.001, 1.004) | <0.001 |
| Blood loss 500 mL | | | | NS |
| Yes | 3.30 (0.98, 11.11) | 0.054 | | |
| No | 1.0 | | | |
| Blood transfusion | | | | NS |
| Yes | 5.0 (1.48, 16.91) | 0.010 | | |
| No | 1.0 | | | |
| Neural invasion | | | | NS |
| Present | 3.30 (0.98, 11.11) | 0.054 | | |
| Absent | 1.0 | | | |
| Vascular invasion | | | | NS |
| Present | 6.51 (1.40, 30.30) | 0.017 | | |
| Absent | 1.0 | | | |
| Lymph node metastasis | | | | NS |
| Present | 4.49 (1.33, 15.15) | 0.016 | | |
| Absent | 1.0 | | | |
| Tumor differentiation | 2.43 (0.66, 8.88) | 0.181 | | |
| Overall stage b | 4.20 (1.45, 12.10) | 0.008 | 4.46 (1.31, 15.17) | 0.017 |
Values in parentheses are 95% confidence intervals.
aLogistic regression. bAmerican Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition. ASA, American Society of Anesthesiologists.